Literature DB >> 27844180

Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women.

Shuai Lin1, Meng Wang1, Xinghan Liu1, Wenge Zhu2, Yan Guo3, Zhiming Dai4, Pengtao Yang1, Tian Tian1, Cong Dai1, Yi Zheng1, Chunyan Hu1, Linyan Wei1, Zhijun Dai5.   

Abstract

Macrophage migration inhibitory factor (MIF) has been reported to associate with increased cancer risk in several cancers. However, the role of MIF in breast cancer (BC) susceptibility remains unknown. For the first time, we conducted a case-control study to assess the potential association of three common MIF gene variants (rs755622, rs1803976, rs11548059) with BC susceptibility in Chinese women. Total 560 breast cancer patients and 583 age- and sex-matched healthy individuals were recruited from Northwest China, and the DNA was genotyped by Sequenom MassARRAY. Odds ratios (OR) and 95% confidence intervals (95% CI) were computed to estimate the associations. We found that C/G, C/C, and C/G-C/C genotype carriers in MIF rs755622 have a significantly increased risk of BC (C/G vs. G/G: OR = 1.36, 95% CI = 1.07-1.75, P = 0.014; C/C vs. GG: OR = 2.01, 95% CI = 1.06-3.79, P = 0.029; C/G-C/C vs. G/G: OR = 1.42 95% CI = 1.11-1.80, P = 0.004). Further analyses indicate that the BC risk is associated with Ki-67 status, and the rs755622 polymorphism increases breast cancer risk among elder patients (≥49 years). There is no association between BC risk and other two polymorphisms (rs1803976 and rs11548059) by overall analysis and stratified analysis. In conclusion, MIF rs755622 polymorphism increases BC susceptibility in Chinese population, especially among elder patients.

Entities:  

Keywords:  Breast cancer; Gene variant; MIF; Susceptibility

Mesh:

Substances:

Year:  2016        PMID: 27844180     DOI: 10.1007/s10238-016-0439-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  24 in total

Review 1.  Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities.

Authors:  Ciaran O'Reilly; Mohammad Doroudian; Leona Mawhinney; Seamas C Donnelly
Journal:  Med Res Rev       Date:  2016-01-18       Impact factor: 12.944

2.  Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis.

Authors:  Tomiyasu Arisawa; Tomomitsu Tahara; Tomoyuki Shibata; Mitsuo Nagasaka; Masakatsu Nakamura; Yoshio Kamiya; Hiroshi Fujita; Daisuke Yoshioka; Yuko Arima; Masaaki Okubo; Ichiro Hirata; Hiroshi Nakano; Vidal De la Cruz
Journal:  Oncol Rep       Date:  2008-01       Impact factor: 3.906

Review 3.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

4.  Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence.

Authors:  K L Meyer-Siegler; P L Vera; K A Iczkowski; C Bifulco; A Lee; P K Gregersen; L Leng; R Bucala
Journal:  Genes Immun       Date:  2007-08-30       Impact factor: 2.676

5.  The association between MIF-173 G>C polymorphism and prostate cancer in southern Chinese.

Authors:  G X Ding; S Q Zhou; Z Xu; N H Feng; N H Song; X J Wang; J Yang; W Zhang; H F Wu; L X Hua
Journal:  J Surg Oncol       Date:  2009-08-01       Impact factor: 3.454

6.  Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis.

Authors:  Pedro L Vera; Katherine L Meyer-Siegler
Journal:  BMC Res Notes       Date:  2011-10-11

7.  The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis.

Authors:  Xiao Zhang; Wenhao Weng; Wen Xu; Yulan Wang; Wenjun Yu; Xun Tang; Lifang Ma; Qiuhui Pan; Jiayi Wang; Fenyong Sun
Journal:  Onco Targets Ther       Date:  2015-03-10       Impact factor: 4.147

8.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.

Authors:  E C Inwald; M Klinkhammer-Schalke; F Hofstädter; F Zeman; M Koller; M Gerstenhauer; O Ortmann
Journal:  Breast Cancer Res Treat       Date:  2013-05-16       Impact factor: 4.872

9.  Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.

Authors:  Vincent Richard; Nadège Kindt; Christine Decaestecker; Hans-Joachim Gabius; Guy Laurent; Jean-Christophe Noël; Sven Saussez
Journal:  Oncol Rep       Date:  2014-06-16       Impact factor: 3.906

Review 10.  MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus.

Authors:  Tali Lang; Andrew Foote; Jacinta P W Lee; Eric F Morand; James Harris
Journal:  Front Immunol       Date:  2015-11-11       Impact factor: 7.561

View more
  10 in total

1.  PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages.

Authors:  Sreedevi Avasarala; Pei-Ying Wu; Samia Q Khan; Su Yanlin; Michelle Van Scoyk; Jianqiang Bao; Alessandra Di Lorenzo; Odile David; Mark T Bedford; Vineet Gupta; Robert A Winn; Rama Kamesh Bikkavilli
Journal:  Mol Cancer Res       Date:  2019-10-16       Impact factor: 5.852

2.  Pleiotropic role of macrophage migration inhibitory factor in cancer.

Authors:  Maheedhara R Guda; Matthew A Rashid; Swapna Asuthkar; Anvesh Jalasutram; John L Caniglia; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

3.  Association of OPG gene polymorphisms with the risk of knee osteoarthritis among Chinese people.

Authors:  Yuxin Qi; Feimeng An; Jiaqi Wang; Yuan Liu; Hongyan Gao; Zhe Ge; Enze Jiang; Donggao Cai; Jianping Shi; Jianzhong Wang
Journal:  Mol Genet Genomic Med       Date:  2019-04-11       Impact factor: 2.183

4.  Association study between genetic polymorphisms in folate metabolism and gastric cancer susceptibility in Chinese Han population: A case-control study.

Authors:  Lusha Wei; Fanglin Niu; Jiamin Wu; Fulin Chen; Hua Yang; Jing Li; Tianbo Jin; Yifei Wu
Journal:  Mol Genet Genomic Med       Date:  2019-03-18       Impact factor: 2.183

5.  Assessment of the association between ACYP2 and laryngeal squamous cell carcinoma risk in Chinese males.

Authors:  Wenhui Zhao; Fanglin Niu; Zhilan Xie; Mengdan Yan; Jingjie Li; Yuan Zhang; Jun Chen; Qiufang Liu; Tianbo Jin
Journal:  Mol Genet Genomic Med       Date:  2019-05-29       Impact factor: 2.183

6.  The influence of ACYP2 polymorphisms on gastrointestinal cancer susceptibility in the Chinese Han population.

Authors:  Xianglong Duan; Jiajing Hong; Fuchun Wang; Kun Wei; Pengyuan Wang; Feng Hou; Min Zhang; Dengfeng Liu; Dongya Yuan; Sida Liu
Journal:  Mol Genet Genomic Med       Date:  2019-05-08       Impact factor: 2.183

7.  Influence of IL-1R2 polymorphisms on endometrial cancer susceptibility in the Chinese Han population.

Authors:  Jiamin Wu; Wenjie Zhang; Junhong Cai; Sizhe Huang; Fanglin Niu; Ying Zhang; Shan Bao; Tianbo Jin
Journal:  Mol Genet Genomic Med       Date:  2019-03-20       Impact factor: 2.183

8.  MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma.

Authors:  Lifeng Qin; Jinmei Qin; Xiaoping Lv; Caiqiao Yin; Qian'e Zhang; Jiqiao Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

Review 9.  Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

Authors:  Eugenio Cavalli; Rosella Ciurleo; Maria Cristina Petralia; Paolo Fagone; Rita Bella; Katia Mangano; Ferdinando Nicoletti; Placido Bramanti; Maria Sofia Basile
Journal:  Molecules       Date:  2020-03-06       Impact factor: 4.411

10.  Association of the genetic variants (-794 CATT5-8 and -173 G > C) of macrophage migration inhibitory factor (MIF) with higher soluble levels of MIF and TNFα in women with breast cancer.

Authors:  Guadalupe Avalos-Navarro; Alicia Del Toro-Arreola; Adrián Daneri-Navarro; Antonio Quintero-Ramos; Luis Alberto Bautista-Herrera; Ramon Antonio Franco Topete; Brian Uriel Anaya Macias; David Israel Javalera Castro; Andrés de Jesús Morán-Mendoza; Antonio Oceguera-Villanueva; Antonio Topete-Camacho; José Francisco Muñoz-Valle
Journal:  J Clin Lab Anal       Date:  2020-01-24       Impact factor: 2.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.